Clinical Trial

Levomilnacipran in Healthy Males

Study Description

Levomilnacipran in Healthy Males

Levomilnacipran is an antidepressant currently approved in Canada to treat Major Depressive Disorder (MDD). Thirty-six healthy male participants will receive escalating doses of levomilnacipran, duloxetine, or placebo every 7 days (+/- 1 day) throughout a 20 - 28 day period. After each dose escalation study participants will be asked to come to the clinic to conduct the necessary tests - these will include tyramine pressor tests as well as blood draws. The results of this study will allow the investigators to determine the dose(s) of levomilnacipran at which reuptake inhibition of norepinephrine and serotonin (chemicals utilized by nerve cells to transmit information to other cells) is achieved.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - Levomilnacipran

Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.

Drug - Duloxetine

Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.

Drug - Placebos

Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.

Additional Information

Official Study Title

Effectiveness of the Norepinephrine and Serotonin Reuptake Inhibitor Levomilnacipran in Healthy Males

Clinical Trial ID

NCT03249311

ParticipAid ID

Rb406b